BioCentury | Feb 27, 2018
Company News

Management tracks: Sotio, EpimAb

Cancer and autoimmune disease company Sotio a.s. (Prague, Czech Republic) said CEO Ladislav Bartonícek will transition to the company's board, effective March 1. He is succeeded by CSO and Co-founder Radek Spíšek. Bi-specific antibody company...
BioCentury | Jan 13, 2014
Company News

Aptalis Holdings, Forest Laboratories deal

...acquire gastrointestinal company Aptalis for $2.9 billion in cash. Aptalis markets nine products, including Carafate sucralfate...
BioCentury | Jan 13, 2014
Finance

Highlights of weekly biotech stock moves

...company Aptalis Holdings Inc. for $2.9 billion in cash. Aptalis markets nine products, including Carafate sucralfate...
BioCentury | Jan 9, 2014
Top Story

Forest to acquire Aptalis

...market cap for a closing valuation of $18.7 billion. Aptalis markets nine products, including Carafate sucralfate...
BioCentury | Dec 27, 2013
Top Story

Aptalis files for $500 million IPO

...IPO underwritten by Goldman Sachs; JPMorgan; Barclays; and Evercore. Aptalis markets nine products, including Carafate sucralfate...
BioCentury | Aug 2, 2010
Regulation

Equivalence test case

...of a drug that is not systemically absorbed. Goshko and Nicholas cited ulcer drug Carafate sucralfate...
...absorbed from the GI tract, as an example where FDA required clinical studies for follow-ons. Carafate...
BioCentury | Aug 2, 2010
Regulation

Equivalence test case

...of a drug that is not systemically absorbed. Goshko and Nicholas cited ulcer drug Carafate sucralfate...
...absorbed from the GI tract, as an example where FDA required clinical studies for follow-ons. Carafate...
BioCentury | Oct 13, 2003
Finance

Ebb & Flow

...million in cash to Aventis (AVE) to acquire North American rights to duodenal ulcer drug Carafate...
BioCentury | Oct 13, 2003
Company News

Axcan, Aventis deal

...AXP acquired North American rights from AVE to duodenal ulcer drug Carafate (Sulcrate in Canada), irritable...
...and hemorrhoidal drug Proctosedyl for $145 million in cash. In 2002, net U.S. sales of Carafate...
BioCentury | Oct 9, 2003
Company News

Axcan, Aventis GI product deal

...Axcan (TSE:AXC; AXCA) acquired North American rights from AVE to duodenal ulcer drug Carafate (Sulcrate in...
...Proctosedyl for a cash purchase price of $145 million. In 2002, total net sales of Carafate...
Items per page:
1 - 10 of 10